The FINANCIAL — Gilead Sciences, Inc. and Novo Nordisk A/S announced results from a phase 2 proof-of-concept trial. The five-arm trial evaluated combinations of Novo Nordisk’s semaglutide, a GLP-1 receptor agonist, with Gilead’s investigational FXR agonist cilofexor and/or Gilead’s investigational ACC inhibitor
More
Georgian distribution company Orbita plans to increase its assortment of snacks this year and offer innovative products to the Georgian market by 2020. General Director of Orbita, Giorgi Davitadze, said that the new assortment of snacks will include hazelnuts blended with different
More